Takara Bio Inc (TKBIF)価格

Takara Bio, Inc. engages in development and marketing of genetic engineering technologies. The company is headquartered in Kusatsu-Shi, Shiga-Ken and currently employs 1,779 full-time employees. The company went IPO on 2004-12-07. The firm has one business segment. The reagents, instruments and contract services business provides biotechnology-related research reagents, laboratory instruments and contract services to universities, research institutions and corporations, offering products in the fields of molecular and cell biology based on technologies including polymerase chain reaction (PCR), next-generation sequencing, genome editing and stem cells. The firm also promotes its contract development and manufacturing organization (CDMO) business, which includes contract manufacturing of regenerative medicine products and genetic analysis services. The gene therapy business advances the development of gene therapy drugs including genetically modified T-cell therapies and next-generation chimeric antigen receptor (CAR) technologies.